A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Theravance Biopharma Theravance Biopharma R & D, Inc.